PetVivo Holdings Business Summary

PetVivo Holdings, Inc. (PETV) is a biomedical device company that generates revenue through the manufacturing, commercialization, and licensing of proprietary biomaterials for the companion animal and equine markets. Its primary business segments include medical devices, led by its flagship product Spryng® with OsteoCushion® Technology—a veterinarian-administered intra-articular injection for osteoarthritis— and regenerative medicine, featuring the off-the-shelf PrecisePRP™ product line. In late 2025, the company diversified its revenue streams by launching PetVivo.ai, a high-margin B2B Software-as-a-Service (SaaS) platform powered by an exclusive 10-year licensing agreement for Digital Landia’s AgenticPet AI technology. PetVivo competes with firms such as Orthomed, RevitaVet, and VetStem in the orthopedic and regenerative veterinary space, positioning itself as a niche leader in non-surgical, long-lasting therapeutic solutions that bridge the gap between traditional pharmaceuticals and invasive surgery. The company was founded in 2009 by John Lai and Tom McEachern, with a strategic focus on adapting human-grade biomaterials for veterinary use. The current leadership team is headed by John Lai, who serves as CEO, President, and Director, bringing over 30 years of executive experience in corporate development and capital markets. He is supported by Garry Lowenthal, who was appointed Chief Financial Officer in March 2024, and John Dolan, the Chief Business Development Officer and General Counsel. A notable recent addition to the Board of Directors is Josh Ruben, Managing Director of Life Sciences at Trinity Capital, who joined in October 2025 to provide expertise in venture lending and M&A strategy. The board also includes seasoned governance professionals such as Robert Costantino and Joseph Jasper, overseeing the company’s expansion into international markets including Canada, Mexico, and the United Kingdom.